Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2009 2
2010 3
2012 2
2013 4
2014 2
2015 5
2016 5
2017 6
2018 5
2019 13
2020 12
2021 11
2022 12
2023 21
2024 15
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for giuseppe pm
Search for Giuseppa PM instead (1 results)
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Smith AE, Angelucci E, Raymakers RAP, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Iori AP, La Rocca U, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, Sicre de Fontbrune F, Marotta S, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Cacace F, Frieri C, van Lint MT, Passweg JR, Marsh JCW, Socié G, Mufti GJ, Dufour C, Risitano AM; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Peffault de Latour R, et al. N Engl J Med. 2022 Jan 6;386(1):11-23. doi: 10.1056/NEJMoa2109965. N Engl J Med. 2022. PMID: 34986284 Clinical Trial.
Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Morganti S, et al. Adv Exp Med Biol. 2019;1168:9-30. doi: 10.1007/978-3-030-24100-1_2. Adv Exp Med Biol. 2019. PMID: 31713162 Review.
NGS provided a significant step forward in Personalized Medicine (PM) by enabling the detection of somatic driver mutations, resistance mechanisms, quantification of mutational burden, germline mutations which settled the foundation of a new approach in cancer care. In thi …
NGS provided a significant step forward in Personalized Medicine (PM) by enabling the detection of somatic driver mutations, resistan …
Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs.
Cardaropoli G, Araújo M, Lindhe J. Cardaropoli G, et al. J Clin Periodontol. 2003 Sep;30(9):809-18. doi: 10.1034/j.1600-051x.2003.00366.x. J Clin Periodontol. 2003. PMID: 12956657
On day 14, the tissue of the socket was comprised of PM and woven bone. On day 30, mineralized bone occupied 88% of the socket volume. This tissue had decreased to 15% on day 180. ...
On day 14, the tissue of the socket was comprised of PM and woven bone. On day 30, mineralized bone occupied 88% of the socket volume …
TFOS Lifestyle Report: Impact of environmental conditions on the ocular surface.
Alves M, Asbell P, Dogru M, Giannaccare G, Grau A, Gregory D, Kim DH, Marini MC, Ngo W, Nowinska A, Saldanha IJ, Villani E, Wakamatsu TH, Yu M, Stapleton F. Alves M, et al. Ocul Surf. 2023 Jul;29:1-52. doi: 10.1016/j.jtos.2023.04.007. Epub 2023 Apr 14. Ocul Surf. 2023. PMID: 37062427
Dry eye disease is associated with air pollution (from NO(2)) and soil pollution (from chromium), but not from air pollution from CO or PM(10). Future research should adequately account for confounders, follow up over time, and report results separately for ocular surface …
Dry eye disease is associated with air pollution (from NO(2)) and soil pollution (from chromium), but not from air pollution from CO or P …
Association of Brain Age, Lesion Volume, and Functional Outcome in Patients With Stroke.
Liew SL, Schweighofer N, Cole JH, Zavaliangos-Petropulu A, Tavenner BP, Han LKM, Hahn T, Schmaal L, Donnelly MR, Jeong JN, Wang Z, Abdullah A, Kim JH, Hutton A, Barisano G, Borich MR, Boyd LA, Brodtmann A, Buetefisch CM, Byblow WD, Cassidy JM, Charalambous CC, Ciullo V, Conforto AB, Dacosta-Aguayo R, DiCarlo JA, Domin M, Dula AN, Egorova-Brumley N, Feng W, Geranmayeh F, Gregory CM, Hanlon CA, Hayward K, Holguin JA, Hordacre B, Jahanshad N, Kautz SA, Khlif MS, Kim H, Kuceyeski A, Lin DJ, Liu J, Lotze M, MacIntosh BJ, Margetis JL, Mataro M, Mohamed FB, Olafson ER, Park G, Piras F, Revill KP, Roberts P, Robertson AD, Sanossian N, Schambra HM, Seo NJ, Soekadar SR, Spalletta G, Stinear CM, Taga M, Tang WK, Thielman GT, Vecchio D, Ward NS, Westlye LT, Winstein CJ, Wittenberg GF, Wolf SL, Wong KA, Yu C, Cramer SC, Thompson PM. Liew SL, et al. Neurology. 2023 May 16;100(20):e2103-e2113. doi: 10.1212/WNL.0000000000207219. Epub 2023 Apr 4. Neurology. 2023. PMID: 37015818 Free PMC article.
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.
Palandri F, Elli EM, Morsia E, Benevolo G, Tiribelli M, Beggiato E, Bonifacio M, Farina M, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Iurlo A, Isidori A, Bosi C, Guglielmana V, Venturi M, Dedola A, Loffredo M, Fontana G, Duminuco A, Moioli A, Tosoni L, Scalzulli E, Cattaneo D, Lemoli RM, Cilloni D, Bocchia M, Pane F, Heidel FH, Vianelli N, Cavo M, Palumbo GA, Branzanti F, Breccia M. Palandri F, et al. Cancer. 2024 Dec 15;130(24):4257-4266. doi: 10.1002/cncr.35489. Epub 2024 Jul 30. Cancer. 2024. PMID: 39078647 Free PMC article.
RESULTS: At baseline (BL), 595 (56.2%) patients were at INT1-risk according to DIPSS (PMF) or MYSEC-PM (SMF). The spleen was palpable at <5 cm, between 5 and 10 cm, and >10 cm below costal margin in 5.9%, 47.4%, and 39.7% of patients, respectively; 300 (54.1%) were h …
RESULTS: At baseline (BL), 595 (56.2%) patients were at INT1-risk according to DIPSS (PMF) or MYSEC-PM (SMF). The spleen was palpable …
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Müller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, Patti F, Grammond P, Buzzard K, Skibina O, Prat A, Girard M, Grand'Maison F, Alroughani R, Lechner-Scott J, Spitaleri D, Barnett M, Cartechini E, Sa MJ, Gerlach O, van der Walt A, Butzkueven H, Prevost J, Castillo-Triviño T, Yamout B, Khoury SJ, Yaldizli Ö, Derfuss T, Granziera C, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group. Müller J, et al. CNS Drugs. 2025 Apr;39(4):403-416. doi: 10.1007/s40263-025-01164-w. Epub 2025 Feb 14. CNS Drugs. 2025. PMID: 39953338 Free PMC article.
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib.
Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, Tiribelli M, Benevolo G, Beggiato E, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Scalzulli E, Duminuco A, Tosoni L, Strazimiri A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT. Palandri F, et al. Cancer. 2025 Sep 1;131(17):e70062. doi: 10.1002/cncr.70062. Cancer. 2025. PMID: 40839414 Free PMC article.
METHODS: To further explore this, the authors performed a subanalysis of the "RUX-MF" study (NCT06516406) with an aim to validate the RR6 and to develop a score specific for intermediate-1 DIPSS/MYSEC-PM risk patients. RESULTS: Among the 776 evaluable patients, 34.4%, 47.8 …
METHODS: To further explore this, the authors performed a subanalysis of the "RUX-MF" study (NCT06516406) with an aim to validate the RR6 an …
Simultaneous Multiple Intracerebral Hemorrhages (SMICH).
Wu TY, Yassi N, Shah DG, Ma M, Sharma G, Putaala J, Strbian D, Campbell BC, Yan B, Tatlisumak T, Desmond PM, Davis SM, Meretoja A. Wu TY, et al. Stroke. 2017 Mar;48(3):581-586. doi: 10.1161/STROKEAHA.116.015186. Stroke. 2017. PMID: 28232593
114 results